Jonathan Goodman, MPhil

Oncology Editor

Jonathan has been the editor of Cancer Therapy Advisor since May 2016. He has a BA in philosophy and neuroscience from Emory University, as well as an MA and MPhil from the University of London, where he studied the philosophy of biology. He has previously worked on prostate cancer research at Memorial Sloan Kettering, and currently researches cultural evolution at CUNY. His work has appeared in Aeon Magazine, The Week, and The Guardian, among other publications.

Most Recent Articles by Jonathan Goodman, MPhil

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

By

Researchers enrolled 222 patients with completely resected stage II-IIIA (N1-N2) NSCLC to receive adjuvant gefitinib or cisplatin plus vinorelbine.

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

By

Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor-negative disease.

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

By

Researchers pooled results from 3 studies, which included 5114 patients with HER2-positive disease, to determine whether 1-year adjuvant trastuzumab yields the optimal OS, DFS, and rate of cardiac events.

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

By

Researchers enrolled 116 patients who were diagnosed with or were suspected of having thyroid cancer. The authors measured the growths' change in diameter to determine a growth pattern.

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

By

For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.

More Articles by Jonathan Goodman, MPhil

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters